AI Verdict
REGN has stronger fundamentals based on our AI analysis.
ABT vs REGN Fundamental Comparison
| Metric | ABT | REGN |
|---|---|---|
| Revenue | $11.2B | $3.6B |
| Net Income | $1.1B | $727.2M |
| Net Margin | 9.6% | 20.2% |
| ROE | 2.1% | 2.3% |
| ROA | 1.0% | 1.8% |
| Current Ratio | 1.39x | 3.57x |
| Debt/Equity | 0.57x | 0.06x |
| EPS | $0.61 | $6.75 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
ABT vs REGN: Frequently Asked Questions
Is ABT or REGN the better stock in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), REGN has stronger fundamentals. ABT is graded B (74% confidence) while REGN is graded A (80% confidence). This is not investment advice.
How does ABT compare to REGN fundamentally?
ABBOTT LABORATORIES has ROE of 2.1% vs REGENERON PHARMACEUTICALS, INC.'s 2.3%. Net margins are 9.6% vs 20.2% respectively.
Which stock pays higher dividends, ABT or REGN?
ABT has a dividend yield of N/A or no dividend while REGN has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in ABT or REGN for long term?
For long-term investing, consider that ABT has a B grade with 74% confidence, while REGN has a A grade with 80% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about ABT vs REGN?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For ABT vs REGN, the AI consensus favors REGN based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.